Hsp90 is a member of the heat shock protein family which assists in protein folding, cell signaling, and tumor repression and is a novel target for oncology and neurodegenerative disorders.
The new generation molecule, initially developed by Nicolas Winssinger at Universite de Strasbourg, has demonstrated efficacy in oncology models.
Provence COO Babak Sayah said an approach involving constant and rigorous project management allowed Provence Technologies’ team to bring NexGenix’s compound to a very advanced stage.
"We put the same level of commitment into the management of NexGenix’s project as we put into our own R&D programs," Sayah said.
NexGenix CEO Allan Rubenstein said working with Provence Technologies has given them the opportunity to achieve their timelines for their lead program, while at the same time using their substantial experience to reduce costs in the process, even at this early stage of development.